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Abstract 
Background: Obstructive lung disease (OLD), a major global public health problem, has been less investigated in 
African countries. We assessed the prevalence and determinants of OLD in Yaounde (the capital city of Cameroon), 
using internationally agreed definitions.
Methods: Participants were adults (age >19 years) screened during a community‑based survey between Decem‑
ber 2013 and April 2014. Air flow limitation (AFL) was based on a pre‑bronchodilator forced expiratory volume in 1 s 
(FEV1) and forced vital capacity (FVC) below the lower limit of normal (LLN, AFL–LLN). Chronic obstructive pulmonary 
disease (COPD) was based on post‑bronchodilator FEV1/FVC ratio < LLN (COPD–LLN).
Results: Of the 1287 subjects included, 51.9 % were female, 9.3 % were current smokers and their mean age was 
34.4 ± 12.8 years. Forty‑nine (3.8 %, 95 % CI 2.8–4.9 %) participants had AFL–LLN. Thirty‑one subjects had COPD–LLN; 
giving a prevalence of COPD–LLN of (2.4 %, 95 % CI 1.6–3.3 %). In multivariable analysis, male gender (AOR 2.42; 95 % 
CI 1.12–5.20) and lifetime wheezing (AOR 2.88; 95 % CI 1.06–7.81) were the determinants of COPD‑LLN. Otherwise, 
male sex (AOR 1.93, 95 % CI 1.00–3.73), age 40–59 years (AOR 1.99, 95 % CI 1.04–3.81) and lifetime wheezing (AOR 
2.65, 95 % CI 1.13–6.20) remained as independent determinants of AFL–LLN.
Conclusions: Obstructive lung disease based on more accurate definitions was relatively infrequent in this popula‑
tion. It is important to sensitize the medical staff and the general public about this condition which should be actively 
investigated in individuals aged 40 years and above.
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Background
Chronic obstructive pulmonary disease (COPD) is a 
major global public health problem. The World Health 
Organization (WHO) has estimated that about 65 million 
people suffer from moderate to severe COPD worldwide 
[1]. A striking issue with COPD is that the condition is 
often underestimated by the patient, and largely under 
diagnosed and as a consequence undertreated by medi-
cal doctors [2]. The prevalence of COPD varies across 
regions and can be as high as 10 % or beyond in regions 
with high prevalence of smoking [3]. COPD is currently 
the fourth leading cause of death globally, and is set 
according to WHO estimates to become the third leading 
cause of death and the fifth provider of disability world-
wide by 2030 [1].
Smoking is the leading risk factor for COPD worldwide 
with the attributable risk fraction of COPD from active 
smoking ranging from 40 to 70 % across countries [4–6].
With an estimated prevalence of smoking ranging from 8 
to 43 % in men and 5 to 30 % in women, and the expand-
ing tobacco industry across the continent, COPD is set 
to become a major health challenge in African countries, 
alongside other communicable and non-communicable 
diseases [7]. Although smoking is a major risk factor 
for COPD, it remains that a large number of those with 
COPD have no history of smoking habits [8, 9]. Other 
contributing factors to the global burden of COPD 
include age greater than 40  years, air pollution, expo-
sure to biomass, exposure to certain gases, low socio-
economic status, genetic factors, history of pulmonary 
tuberculosis and HIV infection [4, 8].
Published studies on COPD largely originate from 
developed countries. Very few epidemiological studies 
have been conducted on COPD in sub-Saharan Africa, 
although COPD represents the fourth cause of death in 
low and middle income countries [10]. Indeed, according 
to WHO’s estimates COPD accounted for 116,000 deaths 
in Africa in 2001, a contribution similar to that observed 
in Europe [11]. In a recent systematic review, Finney et al. 
[6] found only nine cross-sectional studies of acceptable 
methodological quality on COPD in the general popu-
lation in Africa. Efforts to close this knowledge gap will 
have to overcome the challenge of varying definitions of 
air flow obstruction and COPD across recommendations. 
For instance, American Thoracic Society/European Res-
piratory Society (ATS/ERS) recommends that the forced 
expiratory volume in 1  s/forced vital capacity (FEV1/
FVC) ratio < lower limit of normal (LLN) should be used 
to define COPD, while the global initiative for obstruc-
tive lung disease (GOLD) rather recommends that the 
fixed ratio of FEV1/FCV (<0.70) should be used [12, 13]. 
In all instances, demonstrating a chronic airflow obstruc-
tion not fully reversible after bronchodilator inhalation 
is essential to define COPD [3]. It is against this back-
ground that the current study was undertaken with a dual 
objective of: 1) determining the prevalence of obstructive 
lung disease (OLD) including air flow limitation (AFL) 
and COPD in a major city in the Central Africa Region 
according to the different internationally recommended 
definitions; and 2) investigating the determinants of these 
conditions among adults in this setting.
Methods
Type of study, study setting and population
This was a community-based cross-sectional survey 
conducted between December 2013 and April 2014 
(5  months duration) across all the seven districts of 
Yaounde, the Capital City of Cameroon with about 2 mil-
lion inhabitants including 1.4 million adults [14]. Con-
senting adults aged 19 years and above were considered 
for inclusion in the study [15]. They had to be free of 
any of the following conditions: pneumonia in the last 
4 weeks, active thoracic tuberculosis, physical or mental 
impairment affecting the ability to perform spirometry. 
The study was approved by the institutional ethic review 
committee of the Faculty of Medicine and Pharmaceuti-
cal Sciences of the Douala University and the administra-
tive authorities of the Health Delegation for the Centre 
Region.
Sampling
A three level stratified cluster sampling was applied. At 
the first level, 16 enumeration areas (EA, 2–3 per dis-
trict) were selected using a simple random sampling. 
EA demarcations were those used in the third general 
population census conducted in Cameroon in 2005 [14]. 
Each EA comprised about 140–220 households. At the 
second level, one in two household was selected using 
a systematic sampling. The first selected household and 
the itinerary were those used during the national vacci-
nation campaigns. At the third level, all individuals aged 
19  years and above in selected households formed the 
primary statistical unit for data collection.
Data collection
Data were collected by final year undergraduate medical 
students who were specifically trained for this purpose. 
The survey involved fourteen undergraduate final year 
medical students and six spirometry technicians. Data 
collection during face-to-face interviews used a pre-
tested questionnaire, derived from questionnaires used 
in international surveys [16, 17]. Data were collected 
on: 1) socio-demographic characteristics including age, 
sex, level of formal education (none, primary, second-
ary, university), 2) smoking history with participants 
distinguished as non-smokers (including never-smokers 
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and lifetime smoking below 20 packs in their lifetime), 
smokers (including those currently smoking and with 
a lifetime cigarette smoking higher than 20 packs in 
their lifetime), and former-smokers (including those 
who had stopped smoking for over 6  months) [16]; 3) 
past history of respiratory diseases including tubercu-
losis, asthma, chronic bronchitis; 4) chronic respiratory 
symptoms including chronic cough and expectoration 
(lasting for at least 3 months per year), dyspnea which 
was graded in four stages (stage 1—shortness of breath 
while climbing at normal pace on mild inclined surface 
or a floor of the building, stage 2—shortness of breath 
while walking at normal pace with age mates on a flat 
surface, stage 3—shortness of breath while walking at 
own’s pace on a flat surface, stage 4—shortness of breath 
at rest or any small effort); 5) exposure to biomass based 
on the exposure to cooking smoke from solid fuel, and 
was considered as exposed all participants living for 
at least 6  months in a household where solid fuel was 
used for cooking purposes; 6) anthropometric measure-
ments including height (meter) measured to the nearest 
centimeter using a stadiometer, weight (kg) measured 
with a CAMRY scale (CAMRY, Guangzhou, China), 
and body mass index calculated as weight (kg)/[height 
(m)*height (m)].
Spirometric measures
Spirometric data were obtained for all eligible par-
ticipants as per standard methods [18], using turbine 
pneumotachograph (Spiro USB,Care fusion, Yorba 
Linda-USA) or a Fleisch pneumotachograph (Spirolyser 
SPL-10 USB, FIM-Medical, Lyon-France), meeting the 
ATS 1994 standards. All measurements were performed 
after at least 15 min rest, with the participant in a seated 
position, with the back straight, and the nose clipped to 
allow air flow only by mouth. The ATS/ERS acceptabil-
ity and reproducibility criteria were applied [19]. At least 
three tests were done by each participant to establish the 
FVC curve. Spirometric variables measured included: 
FEV1, FVC and the FEV1/FVC ratio. FEV1 and FVC val-
ues retained were the best out of the three tests which 
fulfilled the acceptability criteria (maximal difference 
below 5 % or 150 ml). All participants with a FEV1/FCV 
below the LLN or 0.70 received 400 µg of inhaled salbu-
tamol and had the tests repeated 15  min later to assess 
the reversibility of AFL. Predicted values were estimated 
using the reference spirometric values for an African 
population derived by Musafiri et al. [20]. Quality control 
was done by regularly supervising investigators and tech-
nicians who performed spirometry. Spirometry curves 
were reviewed weekly by one of chest physician involved 
in the study (EWPY and ADB) and feedback was made to 
technicians.
All spirometric tests results were reviewed by an expe-
rienced chest physician (EWPY or ADB).
Operational definitions
Operational definitions were those recommended by the 
ATS/ERS (the use of LLN of FEV1/FVC ratio) [13] or by 
the global initiative for chronic obstructive lung disease 
(GOLD) [fixed cut-off of 0.70 for the FEV1/FVC ratio] 
[21]. Air flow limitation (AFL) was defined by a pre-
bronchodilator FEV1/FVC  < LLN (AFL–LLN) or below 
0.70 (AFL–fixed cut-off). COPD was defined by a post-
bronchodilator FEV1/FVC below the LLN (COPD–LLN) 
or below 0.70 (COPD–fixed cut-off). The severity of AFL 
or COPD was based on the modified 2006 GOLD stages 
[13]: stage I (mild)—FEV1 >80 % of the predicted value; 
Stage II (moderate)—FEV1 comprised between 50–80 % 
of the predicted value; Stage III and IV (severe)—
FEV1 <50 % of the predicted value.
Statistical methods
The sample size was calculated by estimating the popu-
lation of adults aged 19  years and above to be 1.4 mil-
lion. For a type I error of 5  %, an estimated prevalence 
of 4.5  % for COPD [22], and a precision of 1.5  %, the 
required sample size was 733 individuals. Considering a 
correction factor of 1.5 for the cluster effect, and a non-
response rate of 10 %, the final estimated sample size was 
1210 individuals. Data analysis used the IBM-SPSS v.20 
for Windows (IBM, Chicago, USA). Categorical variables 
were presented as count and frequencies, and continuous 
variables as mean and standard deviation (SD) or median 
and 25th–75th percentiles. Group comparisons used Chi 
square test and Fisher exact test for qualitative variables, 
and Student’s t test and equivalents for quantitative vari-
ables. Logistic regression models were used to investigate 
the determinants of AFL and COPD. Significant variables 
in univariable analysis (based on a threshold p  <0.10) 
were entered together in the same multivariable model 
and the significant ones retained as the final determi-




A total of 1612 participants were invited to take part in 
the study, of whom 57 declined, and a further 56 partici-
pants were excluded for a contraindication to spirometry 
or incomplete questionnaires. Of the 1499 participants 
who had spirometric tests done, 212 had incorrect 
maneuvers. Therefore 1287 were included in the final 
analytic sample even though, 11 participants among 
those with a pre-bronchodilator AFL did not have a post-
bronchodilator spirometric test (Fig. 1).
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The baseline characteristics of participants are depicted 
in Table 1. Of the 1287 participants included, 668 (51.9 %) 
were women and 619 (48.1 %) were men. The mean age 
was 34.4  ±  12.8  years. Of the 1283 participants with 
known status for smoking, 9.3 % were smokers and 6.8 % 
were ex-smokers. There were more male than female 
smokers (17 vs 2.3 %, p <0.001). The median (25th–75th 
percentile) quantity of tobacco smoked was 4.3 (1.2–13.7) 
pack-years. Only 28 (15.6  %) smokers and ex-smokers 
had a cumulative quantity of smoked of 20 pack-years or 
more. Dyspnea was more frequent in women (6.1 %) than 
in men (2.7 %), p = 0.003. A history of pulmonary tuber-
culosis was found in 21 (1.6  %) participants. Chronic 
expectoration and lifetime wheezing were found in 0.8 
and 6.6 % of the participants, respectively.
Prevalence and severity of obstructive lung disease
The prevalence of AFL and COPD are shown in Table 1. 
Forty-nine (3.8  %, 95  % CI 2.8–4.9  %) participants had 
AFL–LLN while 9(0.7 %, 95 % CI 0.2–1.2 %) had AFL–
fixed ratio. Thirty-three (69.4 %), 13 (26.5 %) and 2 (4.1 %) 
participants were respectively classified as having mild, 
moderate and severe AFL–LLN.
Thirty-one participants had COPD–LLN, giving a 
prevalence of COPD–LLN of 2.4 % (95 % CI 1.6–3.3 %). 
The prevalence of COPD–fixed ratio was 0.5 % (95 % CI 
0.1–0.9 %). Mild, moderate and severe COPD–LLN was 
respectively found in 67.7, 19.4 and 12.9 % of participants 
with COPD–LLN.
Determinants of air flow limitation
Univariable analysis of determinants of air flow limi-
tation (AFL–LLN) is found in Tables  2. In univariable 
analyses, men were more affected than women (5.2 vs. 
2.5 %, p = 0.014). The prevalence of AFL–LLN was much 
higher in participants aged 40–59  years (5.6  %), and 
60 years and above (7.1 %) than those aged 19–39 years 
(3 %). Ten (20.4 %) participants with AFL–LLN were cur-
rent smokers vs. 110 (8.9 %) in those without AFL–LLN 
(p = 0.008). The prevalence of AFL–LLN was similar in 
participants exposed to biomass than in the non-exposed 
(3.7 vs. 3.9  %, p =  0.893). The prevalence of AFL–LLN 
was higher in participants with self-reported positive 
status for HIV than in those with unknown HIV sta-
tus. Lifetime wheezing was more frequent in partici-
pants with AFL–LLN than in those without (14.3 vs. 
6.3  %, p  =  0.0038). In multivariable analysis including 
all variables with a p value <0.10, male sex (AOR 1.93, 
95  % CI 1.00–3.73), age 40–59  years (AOR 1.99, 95  % 
CI 1.04–3.81) and lifetime wheezing (AOR 2.65, 95  % 
CI 1.13–6.20) remained as independent determinants of 
AFL–LNN (Table 3).
Quality control was done by regularly supervising 
investigators and technicians who performed spirom-
etry. Spirometry curves were reviewed weekly by one of 
chest physician who participated in the study (EWPY and 
ADB) and feedback was made to technicians.
Determinants of COPD
Twenty-one (67.7 %) participants with COPD–LLN and 
587 (47.1 %) participants without COPD–LLN were men 
(p  =  0.023). The prevalence of lifetime wheezing was 
16.1 % among those with COPD–LLN and 6.4 % among 
those without (p =  0.033), Table 4. No significant asso-
ciation was found between pulmonary tuberculosis, HIV 
status, BMI and COPD–LLN (Table 4). In multivariable 
analysis, male gender (AOR 2.42; 95 % CI 1.12–5.20) and 
lifetime wheezing (AOR 2.88; 95  % CI 1.06–7.81) were 
the determinants of COPD–LLN (Table 3).
Discussion
In this study conducted in a major city in sub-Saharan 
Africa using internationally accepted criteria to define 
AFL and COPD, the main findings were the follow-
ing: 1) the prevalence of airway obstruction was 3.8 and 
0.7 % using respectively the LLN and fixed ratio of 0.70 
for FEV1/FVC to define airway obstruction; 2) the preva-
lence of COPD was 2.4 and 0.5 % using respectively the 
LLN and fixed ratio to define COPD; 3) determinants 
of AFL–LLN were male sex, age, and wheezing, while 
4) male sex and wheezing were the determinants of 
COPD–LLN.
Fig. 1 Flow chart for the derivation of the analytic sample
Page 5 of 10Pefura‑Yone et al. BMC Res Notes  (2016) 9:124 
Table 1 Characteristics of subjects included in the study in Yaounde, Cameroun
Characteristics Overall n = 1287 (%) Men n = 619 (%) Women n = 668 (%) p
Age, years
 Mean (SD) 34.4 (12.8) 34.2 (13.1) 34.5 (12.4) 0.309
 Median (25th–75th percentiles) 30 (24–42) 30 (24–42) 31 (25–42) 0.312
 Min–Max 19–83 19–81 19–83 /
Age group, years
 19–39 911 (70.8) 446 (72.1) 465 (69.6) 0.124
 40–59 306 (23.8) 134 (21.6) 172 (25.7)
 ≥60 70 (5.4) 39 (6.3) 31 (4.6)
Level of education
 ≤secondary 854/1285 (66.5) 363/618 (58.7) 491/667 (73.6) <0.001
 Higher education 431/1285 (33.5) 255/618 (41.3) 176/667 (26.4)
Subject/chamber
 ≤2 711/1281 (55.5) 384/617 (62.2) 327/664 (49.2) <0.001
 >2 570:1281 (44.5) 233:617 (37.8) 337/664 (50.8)
Tobacco smoking
 Current smoker 120/1283 (9.4) 105/618 (17) 15/665 (2.3) <0.001
 Ex‑smokers 87/1283 (6.8) 76/618 (12.3) 11/665 (1.7)
 Non smokers 10/1283 (83.9) 437/618 (70.7) 639/665 (96.1)
Cooking fuel
 Clean 557/1252 (44.5) 313/659 (52.8) 244/593 (37) <0.001
 Biomass 99/1252 (7.9) 3/659 (6.6) 60/593 (9.1)
 Mixed 596/1252 (47.6) 241/659 (40.6) 355/593 (53.9)
Past history of TB
 No 1266 (98.4) 608 (98.2) 658 (98.5) 0.692
 Yes 21 (1.6) 11 (1.8) 10 (1.5)
Past history of pneumonia
 No 1250/1286 (97.2) 598/619 (48.1) 652/667 (97.8) 0.214
 Yes 36/1286 (2.8) 21/619 (3.4) 15/667 (2.2)
HIV infection
 No 1005 (78.1) 456 (73.7) 549 (82.2) <0.001
 Yes 11 (0.9) 4 (0.6) 7 (1)
 Don’t know 271 (21.1) 159 (25.7) 112 (16.8)
Chronic cough
 No 1262 (98.1) 607 (98.1) 655 (98.1) 0.992
 Yes 25 (1.9) 12 (1.9) 13 (1.9)
Chronic expectoration
 No 1277 (99.2) 614 (99.2) 663 (99.3) >0.999
 Yes 10 (0.8) 5 (0.8) 5 (0.7)
Chronic dyspnea
 No 1229 (95.5) 602 (97.3) 627 (93.9) 0.003
 Yes 58 (4.5) 17 (2.7) 41 (6.1)
Wheezes
 No 1198/1283 (93.4) 583/617 (48.1) 615/666 (92.3) 0.122
 Yes 85/1283 (6.6) 34/617 (5.5) 51/666 (7.7)
 BMI, kg, mean(SD) 26.4 (5.4) 25.3 (4.3) 27.5 (6.1) <0.001
AFL–pre‑LLN
 Yes 49 (3.8) 32 (5.2) 17 (2.5) 0.014
 No 1238 (96.2) 587 (94.8) 651 (97.5)
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SD standard deviation, HIV human immunodefiency virus, BMI body mass index, AFL airflow limitation, LLN lower limit of normal, COPD chronic obstructive pulmonary 
disease
Table 1 continued
Characteristics Overall n = 1287 (%) Men n = 619 (%) Women n = 668 (%) p
AFL–fixed ratio
 Yes 9 (0.7) 6 (1) 3 (0.4) 0.263
 No 1278 (99.3) 613 (99) 665 (99.6)
COPD–LLN
 Yes 31/1276 (2.4) 21/608 (3.5) 10/668 (1.5) 0.023
 No 1245/1276 (97.6) 587/608 (96.5) 587/668 (96.5)
COPD–fixed‑ratio
 Yes 7/1276 (0.5) 4 (0.7) 3 (0.4) 0.715
 No 1269/1276 (99.5) 604/608 (99.3) 665/668 (99.6)
Table 2 Factors associated to air flow limitation (AFL–LLN) in univariable analysis
Characteristics AFL–LLN n = 49 (%) No AFL n = 1238 (%) COR (95 % CI) p value
Sex
 Male 32 (65.3) 587 (47.4) 2.09 (1.15–3.80) 0.014
 Female 17 (34.7) 651 (52.6) 1
Age, years, m (SD) 39.1 (15.2) 34.2 (12.6) 1.03 (1.01–1.05) 0.008
Age group
 19–39 27 (55.1) 884 (71.4) 1
 40–60 17 (34.7) 289 (23.3) 1.93 (1.03–3.58) 0.036
 ≥60 5 (10.2) 65 (5.3) 2.52 (0.94–6.76) 0.071
Level of education
 ≤Secondary 32/48 (66.7) 822/1237 (66.5) 1.01 (0.55–1.86) 0.975
 Higher education 16/48 (33.3) 415/1237 (33.5) 1
Subject/chamber
 ≤2 26 (53.1) 689/1236 (55.7) 1 0.711
 >2 23 (46.9) 547/1236 (44.3) 1.11 (0.63–1.98)
Tobacco smoking
 Current smoker 10 (20.4) 110/1234 (8.9) 2.70 (1.30–5.61) 0.008
 Ex‑smokers 4 (8.2) 83/1234 (6.7) 1.43 (0.50–4.13) 0.505
 Non smokers 35 (71.4) 1041/1234 (84.4) 1
Cooking fuel
 Biomass 1/43 (2.3) 98/1209 (8.1) 0.32 (0.04–2.46) 0.276
 Mixed 25/43 (58.1) 571/1209 (47.2) 1.39 (0.74–2.60) 0.303
 Clean 17/43 (39.5) 540/1209 (44.7) 1
Past history of TB
 No 48 (98) 1218 (98.4) 1
 Yes 1 (2) 20 (1.6) 1.27 (0.17–9.65) 0.818
Past history of pneumonia
 No 47 (95.9) 1203 (97.3) 1
 Yes 2 (4.1) 34 (2.7) 1.51 (0.35–6.45) 0.582
HIV infection
 No 33 (67.3) 972 (78.5) 1
 Yes 1 (2) 10 (0.8) 2.95 (0.37–23.69) 0.310
 Don’t know 15 (30.6) 256 (20.7) 1.73 (0.92–3.23) 0.087
Chronic cough
 No 48 (98) 1214 (98.1) 1
 Yes 1 (2) 24 (1.9) 1.05 (0.14–7.95) >0.999
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higher than those found in our study. Globally, the preva-
lence of airway obstruction based on pre-bronchodila-
tor’s LLN ranges between 9 and 24 % in the 40 year and 
above age group [24]. The rate of airway obstruction in 
our study based on pre-bronchodilator’s LLN, both in the 
total population and in those aged 40  years and above, 
were at the lower tail of reported figures from around the 
world.
The prevalence of COPD based on a fixed post-bron-
chodilator ratio was 0.5  % in our population, which is 
lower than the 11–25 % reported rate from other regions 
around the world [22, 24, 26]. Based on a more appropri-
ate definition for our young population (i.e. post-bron-
chodilator LLN) to diagnose COPD, the prevalence was 
2.1  % in the general population and 3.2  % among those 
aged 40 years and above [27, 28]. This was lower than the 
7–20 % reported elsewhere [24]. However, it was close to 
the 4.5 % reported by Musafari et al. in Rwanda based on 
the same definition [22].
The overall low prevalence of airway obstruction in 
our study regardless of diagnostic criteria is at least in 
part explained by the low prevalence of smoking in our 
population. In this study, the prevalence of current and 
former smoking was 16.2 % and only 15.6 % of smokers 
and ex-smokers had a cumulative quantity of smoked of 
20 pack-years or more. This is at variance with the very 
high prevalence of smoking in regions with high preva-
lence of COPD [24, 25]. The low prevalence of COPD 
in our study could also be explained by the young age 
of our sample. This young age however is in keeping 
with the age structure of the Cameroon population [14]. 
COPD is more frequent in men than in women in our 
study in accordance with studies from developed coun-
tries [29]. This sex differential was however not found 
in a recent systematic review conducted by Adeloye 
et  al., which included studies from sub-Saharan Africa 
[30]. Other well-known risk factors for COPD such as 
Table 3 Multivariable analysis of  factors associated to  air 
flow limitation and chronic obstructive lung disease
TB tuberculosis, HIV human immunodeficiency virus, AFL air flow limitation, 
COPD chronic obstructive pulmonary disease, LLN lower limit of normal, OR 








 Female 1 1
 Male 1.93 (1.00–3.73) 0.049 2.42 (1.12–5.20) 0.024
Age group, years
 19–39 1 1
 40–59 1.99 (1.04–3.81) 0.037 1.33 (0.57–3.09) 0.504
 ≥60 2.16 (0.79–5.92) 0.134 2.52 (0.82–7.73) 0.106
Tobacco smoking
 Non smokers 1 / /
 Current smoker 1.86 (0.84–4.07) 0.124 / /
 Ex‑smokers 0.81(0.26–2.52) 0.713 / /
HIV infection
 No 1 / /
 Yes 3.94 (0.47–33.21) 0.208 / /
 Don’t know 1.62 (0.85–3.06) 0.140 / /
Lifetime wheezing
 No 1 1
 Yes 2.65 (1.13–6.20) 0.024 2.88 (1.06–7.81) 0.037
m mean, SD standard deviation, TB tuberculosis, BMI body mass index, AFL air flow limitation, LLN lower limit of normal
Characteristics AFL–LLN n = 49 (%) No AFL n = 1238 (%) COR (95 % CI) p value
Chronic expectoration
 No 48 (98) 1229 (99.3) 1
 Yes 1 (2) 9 (0.7) 2.85 (0.35–22.91) 0.323
Chronic dyspnoea 1
 No 48 (98) 1181 (95.4) 1
 Yes 1 (2) 57 (4.6) 0.43 (0.06–3.18) 0.722
Lifetime wheezing
 No 42 (85.7) 1156/1234 (93.7) 1
 Yes 7 (14.3) 78/1234 (6.3) 2.47 (1.08–5.68) 0.038
BMI, kg, m(SD) 25.8 (4.4) 26.5 (5.45) 0.98 (0.92–1.03) 0.410
Table 2 continued
The few available studies on OLD in urban Africa 
using a pre-bronchodilator FEV1/FVC  <0.70 to define 
airway obstruction [23, 24] include a study from Nigeria 
in 2002 and a study from South Africa in 2009 in which 
the prevalences of airway obstruction were 9.3 and 26 % 
respectively. In the USA, the prevalence of bronchial 
obstruction based on a fixed pre-bronchodilator ratio has 
been reported to be about 20.9 % [25]. These rates were 
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pulmonary tuberculosis, HIV infection, exposure to 
biomass were not associated with LLN–COPD in our 
study, likely reflecting the low statistical power due to 
the low prevalence of those characteristics in the gen-
eral population.
The potential limitations of this study include the small 
number of participants’ age 40 years and above, and the 
inclusion of participants exclusively from urban areas. 
However, considering that non-tobacco related determi-
nants of COPD can operate at any age, the inclusion in 
Table 4 Factors associated to chronic obstructive pulmonary disease (COPD–LLN) in univariable analysis
OR odd’s ration, M mean, SD standard deviation, TB tuberculosis, BMI body mass index, COPD chronic obstructive pulmonary disease, LLN lower limit of normal
Characteristics COPD n = 31 (%) No COPD n = 1245 (%) OR (95 % CI) p value
Sex
 Male 21 (67.7) 587 (47.1) 2.35 (1.10–5.04) 0.023
 Female 10 (32.3) 658 (52.9) 1
Age, years, m (SD) 38.5 (14.1) 34.2 (12.7) 1.02 (1.00–1.05) 0.071
Age group
 19–39 19 (61.3) 887 (71.2) 1
 40–60 8 (25.8) 292 (23.5) 1.28 (0.55–2.95) 0.564
 ≥60 4 (12.9) 66 (5.3) 2.83 (0.94–8.56) 0.066
Level of education
 ≤Secondary 21/30 (70) 825/1244 (66.3) 1.19 (0.54–2.61) 0.673
 Higher education 9/30 (30) 419/1244 (33.7) 1
Subject/chamber
 ≤2 16 (61.6) 695/1243 (55.9) 1 0.634
 >2 15 (48.4) 548/1243 (44.1) 0.84 (0.41–1.72)
Tobacco smoking
 Current smoker 4 (12.9) 113/1241 (9.1) 1.55 (0.53–4.52) 0.432
 Ex‑smokers 3 (9.7) 84/1241 (6.8) 1.55 (0.46–5.27) 0.479
 Non smokers 24 (77.4) 1044/1241 (84.1) 1
Cooking fuel
 Clean 9/27 (33.3) 544/1214 (44.8) 1
 Biomass 1 (3.7) 97 (8) 0.62 (0.08–4.97) 0.655
 Mixed 17 (63) 573 (47.2) 1.79 (0.79–4.06) 0.161
Past history of TB
 No 30 (96.8) 1226/1245 (98.5) 1
 Yes 1 (3.2) 19/1245 (1.5) 2.15 (0.28–16.60) 0.391
Past history of pneumonia
 No 30 (96.8) 1209/1244 (97.2) 1
 Yes 1 (3.2) 35/1244 (2.8) 1.15 (0.15–8.68) 0.891
HIV infection
 No 20 (64.5) 977/1245 (78.5) 1
 Yes 1 (3.2) 10/1245 (0.8) 4.86 (0.60–40.00) 0.139
 Don’t know 10 (32.3) 258/1245 (20.7) 1.89 (0.88–4.10) 0.105
Chronic cough/expectoration
 No 30 (96.8) 1219/1245 (97.9) 1
 Yes 1 (3.2) 26/1245 (2.1) 1.56 (0.21–11.89) 0.489
Chronic dyspnea
 No 30 (96.8) 1188/1245 (95.4) 1
 Yes 1 (3.2) 57/1245 (4.6) 0.70 (0.09–5.19) >0.999
Lifetime wheezing
 No 26 (83.9) 1161/1241 (93.6) 1
 Yes 5 (16.1) 80 (6.4) 2.79 (1.04–7.46) 0.033
 BMI, kg, m(SD) 27.2 (4.6) 26.4 (5.5) 1.02 (0.96–1.09) 0.445
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prevalence studies of COPD of a much broader age range 
is justified. Exposure to biomass is usually more impor-
tant in rural than urban areas, and it is possible that 
including rural participants could modify some of our 
findings. van Gemert et al. have recently found the COPD 
prevalence to be 16.2 % in rural Uganda region with high 
level of biomass utilisation [31]. Our study also has major 
strengths. It is the first study in Cameroon and the entire 
central Africa region to use spirometry to assess the pop-
ulation burden of COPD. It is therefore a useful addition 
to existing studies on this topic from Africa [6, 30].
Conclusions
Airway obstruction was relatively low in this central Afri-
can population with low smoking habits, with substantial 
evidence that the prevalence increased with advanced 
age. It is important to sensitize the population and deci-
sion maker on this likely growing health treats. Larger 
studies comprising rural participants are needed to refine 
the findings from the current study.
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